Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2025-12-25 @ 1:43 AM
NCT ID:
NCT04482894
Eligibility Criteria:
Inclusion Criteria:
1. Ability to provide informed consent
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Any of the following:
1. Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.
OR
2. Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
OR
3. Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.
Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.
Exclusion Criteria:
1\. Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04482894
Study Brief:
Protocol Section:
NCT04482894